Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Resovist®' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Resovist®' found in 1 term [] and 2 definitions []
1 - 3 (of 3)     
Result Pages : [1]
MRI Resources 
Liver Imaging - Open Directory Project - Breast Implant - Bioinformatics - Implant and Prosthesis -
 
Resovist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Resovist® is an organ-specific MRI contrast agent, used for the detection and characterization of especially small focal liver lesions.
Resovist® consists of superparamagnetic iron oxide (SPIO) nanoparticles coated with carboxydextran, which are accumulated by phagocytosis in cells of the reticuloendothelial system (RES) of the liver. The uptake of Resovist® Injection in the reticuloendothelial cells results in a decrease of the signal intensity of normal liver parenchyma on both T2- and T1 weighted images.
Most malignant liver tumors do not contain RES cells and therefore do not uptake the iron particles. The resulting imaging effect is an improved contrast between the tumor (bright) and the surrounding tissue (dark).
Resovist® can be injected as an intravenous bolus, which allows immediate imaging of the liver and reduces the overall examination time. A dynamic imaging strategy after bolus injection supports to characterize lesions. In comprehensive clinical trials, it demonstrated an excellent safety profile.
In 2001, Resovist® was approved for the European market.

See also Superparamagnetic Iron Oxide.

Resovist® competed with Primovist™, the other liver imaging agent of Bayer Schering Pharma AG. Due to this reason, the production of Resovist® has been abandoned in 2009.
Drug Information and Specification
NAME OF COMPOUND
Ferrixan [Ferucarbotran], carboxydextran coated iron oxide nanoparticles
CENTRAL MOIETY
Fe2+
CONTRAST EFFECT
T2/T1, Predominantly negative enhancement
r1=25.4, r2=151,
PHARMACOKINETIC
RES-directed
333 mosm/kg
CONCENTRATION
0.5 mol Fe/L
DOSAGE
Less than 60 kg = 0.9 ml, greater than 60 kg = 1.4 ml
PREPARATION
Finished product
INDICATION
Liver lesions
DISTRIBUTOR
See below
PRESENTATION
Pre-filled syringes of 0.9 and 1.4 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA
Resovist®
?
-
Japan
Resovist®
approved
-
EU
Resovist®
approved
-
Australia
Resovist®
Approved
-
spacer
 
• Share the entry 'Resovist®':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  News & More:
Optimized Labelling of Human Monocytes with Iron Oxide MR Contrast Agents
Sunday, 30 November 2003   by rsna2003.rsna.org    
MRI Resources 
Case Studies - Spine MRI - Spectroscopy pool - Colonography - Abdominal Imaging - Sequences
 
Bayer Schering Pharma AGMRI Resource Directory:
 - Manufacturers -
 
www.bayerscheringpharma.de/scripts/pages/en/index.php The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.

MRI Contrast Agents:
Contact Information
MAIL
Bayer Schering Pharma AG
51368 Leverkusen
GERMANY
PHONE
+49-30-46-81-2431
FAX
+49-30-46-81-8195
spacer

• View the DATABASE results for 'Bayer Schering Pharma AG' (22).Open this link in a new window


• View the NEWS results for 'Bayer Schering Pharma AG' (25).Open this link in a new window.
 
Further Reading:
  News & More:
Drastic market changes with MRI contrast media and PET radiopharmaceuticals emerging as most promising segments
Thursday, 21 October 2004   by www.news-medical.net    
Epix Pharmaceuticals to shut down
Tuesday, 21 July 2009   by boston.bizjournals.com    
MRI Resources 
Brain MRI - General - Hospitals - Implant and Prosthesis - Bioinformatics - Equipment
 
Superparamagnetic Iron OxideInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
(SPIO) Relatively new types of MRI contrast agents are superparamagnetic iron oxide-based colloids (median diameter greater than 50nm). These compounds consist of nonstoichiometric microcrystalline magnetite cores, which are coated with dextrans (in ferumoxide) or siloxanes (in ferumoxsil). After injection they accumulate in the reticuloendothelial system (RES) of the liver (Kupffer cells) and the spleen. At low doses circulating iron decreases the T1 time of blood, at higher doses predominates the T2* effect.
SPIO agents are much more effective in MR relaxation than paramagnetic agents. Since hepatic tumors either do not contain RES cells or their activity is reduced, the contrast between liver and lesion is improved. Superparamagnetic iron oxides cause noticeable shorter T2 relaxation times with signal loss in the targeted tissue (e.g., liver and spleen) with all standard pulse sequences. Magnetite, a mixture of FeO and Fe2O3, is one of the used iron oxides. FeO can be replaced by Fe3O4.
Use of these colloids as tissue specific contrast agents is now a well-established area of pharmaceutical development. Feridex®, Endorem™, GastroMARK®, Lumirem®, Sinerem®, Resovist® and more patents pending tell us that the last word in this area is not said.
Some remarkable points using SPIO:
•
A minimum delay of about 10 min. between injection (or infusion) and MR imaging, extends the examination time.
•
Cross-section flow void in narrow blood vessels may impede the differentiation from small liver lesions.
•
Aortic pulsation artifacts become more pronounced.


See also Superparamagnetism, Superparamagnetic Contrast Agents and Classifications, Characteristics, etc..
spacer

• View the DATABASE results for 'Superparamagnetic Iron Oxide' (32).Open this link in a new window


• View the NEWS results for 'Superparamagnetic Iron Oxide' (3).Open this link in a new window.
 
Further Reading:
  Basics:
IMAGE CONTRAST IN MRI(.pdf)
   by www.assaftal.com    
  News & More:
How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol
Saturday, 5 February 2022   by www.ncbi.nlm.nih.gov    
Polysaccharide-Core Contrast Agent as Gadolinium Alternative for Vascular MR
Monday, 8 March 2021   by www.diagnosticimaging.com    
Poly (dopamine) coated superparamagnetic iron oxide nanocluster for noninvasive labeling, tracking, and targeted delivery of adipose tissue-derived stem cells
Tuesday, 5 January 2016   by www.nature.com    
Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer
Wednesday, 11 July 2012   by www.biomedcentral.com    
MRI Resources 
Online Books - Image Quality - Spectroscopy - Non-English - RIS - Shielding
 
     1 - 3 (of 3)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



Next big thing in MRI will be :
AI 
remote operator 
personalized protocols 
helium-free 
molecular MRI 
portable MRI 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 29 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]